Pharmaceutical Market Europe • April 2025 • 37
APPOINTMENTS
MHRA
Lawrence Tallon
The Medicines and Healthcare products Regulatory Agency (MHRA) has appointed Lawrence Tallon as chief executive officer. Tallon holds a wealth of experience from across the healthcare sector and most recently served as deputy chief executive of Guy’s and St Thomas’ NHS Foundation Trust. Prior to this, Lawrence held the position of managing director of the Shelford Group, a collaboration of ten of the largest teaching and research NHS hospital Trusts in England, which gave him insight into the challenges facing modern healthcare and life sciences systems. He also previously served as director of strategy, planning and performance at University Hospitals Birmingham NHS Foundation Trust, and worked alongside ministers and NHS leaders within the Department of Health and Social Care.
3T Biosciences
Marvin Gee
3T Biosciences has appointed Marvin Gee as chief research officer. Gee is a co-founder of 3T and previously served as vice president and head of research at the company. He holds more than a decade of experience across T-cell receptor biology, immunology, structural biology, protein engineering, bioinformatics and machine learning.
3T Biosciences
Barbara Sennino
3T Biosciences has appointed Barbara Sennino as senior vice president and head of early development. Sennino has more than 15 years of experience from both industry and academia, and was most recently vice president of immunotherapy at Turnstone Biologics. She has also held roles at PACT Pharma, culminating in her position as senior director of tumour immunology.
Asgard Therapeutics
Shane Olwill
Asgard Therapeutics has appointed Shane Olwill as chief development officer. Olwill joins the company from Pieris Pharmaceuticals, where he most recently served a senior vice president, chief development officer. Olwill held multiple roles at Pieris, which recently merged with Palvella Therapeutics, including the position of senior vice president, head of translational research.
DSRU
Linda Härmark
The Drug Safety Research Unit (DSRU) has appointed Linda Härmark as director. Härmark joins the DSRU from the Netherlands Pharmacovigilance Centre Lareb, where she has most recently been serving as deputy director. Härmark is a pharmacist by training and brings more than 20 years of pharmacovigilance experience to the role.
Stoke Therapeutics
Arthur Tzianabos
Stoke Therapeutics has appointed Arthur Tzianabos as interim executive chairman of the board. Tzianabos, who has been serving as chair of the company's board for over six years, is currently chief executive officer of Lifordi Immunotherapeutics. Previously, he held the position of president, and also served as chief executive officer, of Homology Medicines.
Infinitopes
Dan Menichella
Infinitopes has appointed Dan Menichella as non-executive director. Menichella brings extensive industry experience to the board, having recently been chief executive officer of Kaleido Biosciences. He previously served as chief executive officer and chief business officer of CureVac’s US subsidiary, and as chief business officer of both Bamboo Therapeutics and AGTC.
Infinitopes
Jo Brewer
Infinitopes has appointed Jo Brewer as non-executive director. Brewer joins the board with over 20 years of experience. She currently serves as chief scientific officer at Adaptimmune, after serving as its senior vice president of allogeneic research. Prior to this, she held a series of senior managerial roles within Adaptimmune’s research organisation.
IsomAb
Shi Yin Foo
IsomAb has appointed Shi Yin Foo as non-executive director. Yin Foo is a cardiologist and immunologist with over 20 years of experience as a practising physician. She is the scientific founder and chief executive officer of Arvada Therapeutics, and has held executive roles at companies including Novartis, Cardioxyl Pharmaceuticals and Imara Therapeutics.
Pharmaceutical Market Europe (PME)
Pharmaceutical industry news, articles, jobs, reports, advice and services